

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 2

ATTORNEY DOCKET NO.

3077/0A/US

SERIAL NO.

10/718,328

APPLICANT

Chandrakumar et. al

FILING DATE

November 20, 2003

GROUP

~~Unknown~~ 1653

## U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	DL	5,120,859	06/09/1992	Webb	548/557	09/22/1989
2.	DL	5,688,913	11/18/1997	Arrhenius	530/330	05/05/1995

## FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
3.	DL	WO 97 08145	03/06/1997	PCT	C07D 213/55		
4.		CA 2,211,270	07/23/1997	Canada	C07D 233/44		
5.		WO 98 08840	03/05/1998	PCT	C07D 401/06		
6.		WO 91 04247	04/04/1991	PCT	C07D 207/16		
7.	DL	EP 0 820 991 A2	01/28/1998	Europe	C07D 239/16	X abstract	

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
8.	DL	Carron, <i>Cancer Res</i> 58, 1930-35, 1988
9.		Dutta, <i>Journal of Peptide Science</i> 6(7): 321-341, July 2000
10.		Komoriya, A., <i>J. Biol. Chem.</i> 266(23):15075-15079, August 1991
11.		Haworth, D., <i>Br. J. Pharmacol.</i> 126(8), 1751-1760, April 1999
12.		Yang Y., <i>European Journal of Immunology</i> 28(3), 995-1004, March 1998
13.	DL	Haubner, <i>J. Am. Chem. Soc.</i> 118, 7881, 1996


Examiner:

Date Considered:

6-8-05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EVT 298497168-05



FORM PDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET NO.

3077/0A/US

SERIAL NO.

10/718,328

APPLICANT

Chandrakumar et. al

FILING DATE

November 20, 2003

GROUP

Unknown 1653

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
14.	<i>DL</i>	Nicosia, <i>American Journal of Pathology</i> 138(4) 829-33, April 1991
15.	<i>DL</i>	Belo, <i>Inflammation</i> 25(2) 91-6, 2001
16.	<i>DL</i>	Mundhenke, <i>Clinical Cancer Research</i> 7(11) 3366-74, 2001
17.	<i>X</i>	Seftor et al., Role of the $\alpha_v\beta_3$ integrin in human melanoma cell invasion, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 1557-1561, March 1992
18.	<i>X</i>	Montgomery et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 8856-8860, September 1994
19.	<i>X</i>	Brooks et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, <i>Cell</i> , Vol. 79, pp. 1157-1164, December 1994
20.	<i>X</i>	Adamis et al., Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy, <i>American Journal of Ophthalmology</i> , Vol. 118, pp. 445-450, October 1994
21.	<i>X</i>	Peacock et al., Angiogenesis Inhibition Suppresses Collagen Arthritis, <i>J. Exp. Med.</i> , Vol. 175, pp. 1135-1138, April 1992
22.	<i>X</i>	Brooks et al., Requirement of Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis, <i>Science</i> , Vol. 264, pp. 569-571, April 1994
23.	<i>X</i>	Sato et al., Echistatin Is a Potent Inhibitor of Bone Resorption in Culture, <i>J. Cell Biology</i> , Vol. 111, pp. 1713-1723, October 1990
24.	<i>X</i>	Fisher et al., Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, an "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, <i>Endocrinology</i> , Vol. 132, No. 3, pp. 1411-1413, 1993
25.	<i>X</i>	Choi et al., Inhibition of neointimal hyperplasia by blocking $\alpha_v\beta_3$ integrin with a small peptide antagonist GpenGRGDSPCA, <i>J. Vasc. Surg.</i> , Vol. 19(1), pp. 125-134, 1994
26.	<i>X</i>	White, J.M., Integrins as virus receptors, <i>Current Biology</i> , Vol. 3(9), pp. 596-599, 1993

*David L. Khan*

6-8-05

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.